The 2022 Clinical Trials on Alzheimer’s Disease (CTAD) conference has been a truly historic meeting, and the Alzheimer’s Drug Discovery Foundation (ADDF)’s role in bringing about a new era of research was evident throughout.
Five previous winners of the prestigious Melvin R. Goodes Prize came together in New York City recently to honor this year’s winner, Miranda E. Orr, PhD, Assistant Professor of Gerontology and Geriatric Medicine at the Wake Forest University School of Medicine, and to discuss how their research is working toward the same goal – to conquer Alzheimer’s.
Earlier this year, two outstanding researchers, Paul Fish, Ph.D., and Paul Worley, M.D., were selected by the ADDF and Harrington Discovery Institute to receive ADDF-Harrington Scholar Awards.
The FDA made a landmark decision on June 7, approving aducanumab (Aduhelm™, Biogen) for the treatment of Alzheimer’s disease. Aducanumab is the first new Alzheimer’s treatment in 17 years and the first ever shown to modify the course of the disease.
I sat down with two outstanding ADDF-funded researchers recently to talk about the latest news on their cutting-edge work, the inspiration for their ideas, and when we can expect results from their latest trials.
This year tested us like no other, but from great challenges came innovation and creativity as we drove forward our mission to identify new therapies to prevent and treat Alzheimer’s disease.
The Alzheimer’s Drug Discovery Foundation’s venture philanthropy model has a singular mission: to invest money and resources in bold ideas that can speed development of drugs for Alzheimer’s.
A study published last week in Neurology, “Sex-Driven Modifiers of Alzheimer Risk,” provides new insights into why women are more than twice as likely as men to develop Alzheimer’s disease.
As the 2019 recipient of the ADDF-Harrington Scholar Award, Dr. Eugenia Trushina of Mayo Clinic Rochester not only receives funding, but also in-depth advisory support from pharmaceutical industry experts on the Harrington team.
Over the past year, we have had many reasons to be proud of the promising work supported by the ADDF. The following is a summary of what I see as the ADDF’s most important science and research involvements of 2019. As we close out the decade, I am encouraged that we are moving closer to viable therapies and prevention strategies for Alzheimer’s disease.
By any definition, Pamela J. Newman, Ph.D. and her late husband Henry (Hank) Kates were a power couple. But when Alzheimer’s struck Hank, suddenly the Newman-Kates family felt powerless. Together, they valiantly fought the disease until Hank’s death in 2016 at age 77. For years, Dr. Newman has been an ardent supporter of Alzheimer’s research and ADDF, serving on the Board of Overseers since 2013. In recognition of her dedication, we recently honored Pamela with the Charles Evans Award at the Tenth Annual “Hope on the Horizon” Fall Symposium & Luncheon in New York City.
Chief Medical Officer at Amylyx Pharmaceuticals gives a closer look at how far they have come in their recently expanded phase 2 clinical trial, supported in part by the ADDF, which is studying a combination approach to treating people with Alzheimer’s disease.
At the ADDF's Ninth Annual Fall Symposium, Richard S. Isaacson, Michelle M. Mielke, and Mark A. Mintun discussed Alzheimer's biomarkers and prevention.
With funding from the ADDF since 2004, Dr. Roberta Diaz Brinton has developed what may become the first ever regenerative treatment for Alzheimer's disease.
Wednesday marked the beginning of National Alzheimer's Disease Awareness Month and the 10th Clinical Trials on Alzheimer's Disease conference, which featured a record amount of research we supported.
Since 1998, the ADDF has invested over $100 million in the best ideas to cure Alzheimer's. We are seeing the impact of our efforts, with many promising drugs in clinical trials on the way.
Dr. Michela Gallagher of Agenebio is developing AGB101, which can potentially prevent mild cognitive impairment from progressing to Alzheimer's disease.
We have supported over 20% of all Alzheimer's treatments currently in clinical trials. One of the most promising is C-31, developed by Frank Longo, MD, PhD.
Eli Lilly announced that its Alzheimer's drug solanezumab failed in its last phase 3 clinical trial. Howard Fillit, MD, discusses what this means, and where we go from here.
Ernest Scheyder, a returning member of our TCS NYC Marathon team, shares why he is running for Alzheimer’s research and how you can help our dedicated runners.
Karen Mason reflects on her late husband, Tommy Mason, whom she describes as "larger than life," a trait that remained even as he endured the effects of Alzheimer’s.
With support from the ADDF, Carmela Abraham, PhD recently founded Klogene to accelerate the development of a new class of drugs to combat Alzheimer’s disease.
Partnerships increase our funding power and our combined expertise—ultimately, ensuring that we can get to a cure for Alzheimer’s and related dementias faster.
As a parent, it wouldn't take much evidence for me to keep my children out of high-impact sports like football and soccer. But as a scientist and a physician, I have a different perspective.
Dr. Roberta Diaz Brinton and Dr. Howard Fillit discuss the latest in Alzheimer’s research and drug development in a recent episode of Alzheimer’s Talks.
Loss is a natural part of caring for an Alzheimer's patient. These brave men and women facing Alzheimer's have lost many things in their lives. Love isn't one of them.
In 2014, we had a transformative year, advancing drugs for Alzheimer's, supporting the best science, and ensuring people have information to protect their brain health.
The ADDF and the Alzheimer’s Society UK have teamed up to support a trial of an erectile dysfunction drug as a possible treatment for vascular dementia.
The Cystic Fibrosis Foundation received a record-breaking $3.3 billion return on its early investment in research that led to the first FDA-approved drug to treat the causes of cystic fibrosis.
This Thanksgiving, we are grateful for the support of our donors, which has enabled the ADDF to make tremendous progress in our search for a cure for Alzheimer’s disease.
Researchers at Massachusetts General Hospital successfully created a laboratory model of Alzheimer's, which may be a more accurate way to screen prospective drugs.
John O’Keefe, May-Britt Moser, and Edvard Moser, have been awarded the 2014 Nobel Prize in Physiology or Medicine for their discoveries of place and grid cells in the brain.
Leonard A. Lauder explains why he and his brother, Ronald, co-founded the ADDF, and why they need your help to fulfill its mission of conquering Alzheimer's disease.
Our neuroscientists share highlights from their favorite sessions at the 2014 Alzheimer’s Association International Conference (AAIC) in Copenhagen, Denmark.
Researchers have identified a promising new drug that prevents abnormal blood clots in the brain, reduces cerebral inflammation, and improves memory in preclinical studies.
The widespread misconception that Alzheimer's disease is a typical part of aging has serious ramifications for people's health and research into a cure.
My husband and I had been together 26 years when he became one of nearly six million North Americans diagnosed with Alzheimer’s disease. Seven years later, I was an Alzheimer’s widow.
A recent New York Times Op-Ed highlights that, while it's possible to "repurpose" available drugs to treat patients, we don't test them because "no one stands to make money."
A study from Tufts Medical Center adds to the growing body of evidence suggesting that it is possible to lower one’s risk of developing Alzheimer’s disease.
We've known for years that the number of deaths caused by Alzheimer's disease has been underreported. A recent study suggests it may be the third-leading cause of death in the U.S.
In 2013, the ADDF funded nearly 40 drug research programs around the world. We look forward to continuing to advance the most promising Alzheimer’s research and improving the lives of millions around the world.
I recently saw a patient who was afraid he had Alzheimer's disease. A new scan made it easy to give him an accurate diagnosis. So why can't most patients use it?
The current costs of dementia care are enormous. But the future costs could create a crippling financial burden on our society, as the number of people diagnosed with dementia is expected to more than double in the next 30 years.
Search
View More